Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Competitors & Peer Comparison
See (RXRX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RXRX | $5.48 | +2.24% | 2.3B | -2.92 | -$1.81 | N/A |
| VRTX | $385.65 | +5.21% | 96B | 26.60 | $14.08 | N/A |
| ALNY | $428.14 | -2.46% | 57B | -176.83 | -$2.46 | N/A |
| REGN | $555.13 | -1.40% | 56.9B | 13.76 | $39.69 | +0.32% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $673.15 | +1.71% | 39.1B | 32.47 | $19.66 | N/A |
| BNTX | $111.30 | -0.32% | 26.3B | -65.82 | -$1.66 | N/A |
| SMMT | $28.52 | -0.49% | 21B | -83.09 | -$0.34 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
RXRX vs VRTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, VRTX has a market cap of 96B. Regarding current trading prices, RXRX is priced at $5.48, while VRTX trades at $385.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas VRTX's P/E ratio is 26.60. In terms of profitability, RXRX's ROE is -0.76%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, RXRX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check VRTX's competition here
RXRX vs ALNY Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ALNY has a market cap of 57B. Regarding current trading prices, RXRX is priced at $5.48, while ALNY trades at $428.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ALNY's P/E ratio is -176.83. In terms of profitability, RXRX's ROE is -0.76%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, RXRX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ALNY's competition here
RXRX vs REGN Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, REGN has a market cap of 56.9B. Regarding current trading prices, RXRX is priced at $5.48, while REGN trades at $555.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas REGN's P/E ratio is 13.76. In terms of profitability, RXRX's ROE is -0.76%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RXRX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check REGN's competition here
RXRX vs SGEN Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RXRX is priced at $5.48, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RXRX's ROE is -0.76%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RXRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check SGEN's competition here
RXRX vs ARGX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ARGX has a market cap of 39.1B. Regarding current trading prices, RXRX is priced at $5.48, while ARGX trades at $673.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ARGX's P/E ratio is 32.47. In terms of profitability, RXRX's ROE is -0.76%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, RXRX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ARGX's competition here
RXRX vs BNTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, BNTX has a market cap of 26.3B. Regarding current trading prices, RXRX is priced at $5.48, while BNTX trades at $111.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas BNTX's P/E ratio is -65.82. In terms of profitability, RXRX's ROE is -0.76%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, RXRX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check BNTX's competition here
RXRX vs SMMT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, SMMT has a market cap of 21B. Regarding current trading prices, RXRX is priced at $5.48, while SMMT trades at $28.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas SMMT's P/E ratio is -83.09. In terms of profitability, RXRX's ROE is -0.76%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, RXRX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check SMMT's competition here
RXRX vs BGNE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RXRX is priced at $5.48, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RXRX's ROE is -0.76%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, RXRX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check BGNE's competition here
RXRX vs DNA-WT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RXRX is priced at $5.48, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RXRX's ROE is -0.76%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, RXRX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check DNA-WT's competition here
RXRX vs INCY Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, INCY has a market cap of 15.5B. Regarding current trading prices, RXRX is priced at $5.48, while INCY trades at $77.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas INCY's P/E ratio is 18.72. In terms of profitability, RXRX's ROE is -0.76%, compared to INCY's ROE of +0.34%. Regarding short-term risk, RXRX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check INCY's competition here
RXRX vs RPRX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RPRX has a market cap of 15.2B. Regarding current trading prices, RXRX is priced at $5.48, while RPRX trades at $37.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RPRX's P/E ratio is 15.80. In terms of profitability, RXRX's ROE is -0.76%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, RXRX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check RPRX's competition here
RXRX vs GMAB Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, GMAB has a market cap of 13.7B. Regarding current trading prices, RXRX is priced at $5.48, while GMAB trades at $21.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas GMAB's P/E ratio is 10.92. In terms of profitability, RXRX's ROE is -0.76%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, RXRX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check GMAB's competition here
RXRX vs UTHR Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, UTHR has a market cap of 13.6B. Regarding current trading prices, RXRX is priced at $5.48, while UTHR trades at $302.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas UTHR's P/E ratio is 11.72. In terms of profitability, RXRX's ROE is -0.76%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RXRX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check UTHR's competition here
RXRX vs KRTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RXRX is priced at $5.48, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RXRX's ROE is -0.76%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RXRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check KRTX's competition here
RXRX vs ASND Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ASND has a market cap of 11.9B. Regarding current trading prices, RXRX is priced at $5.48, while ASND trades at $182.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ASND's P/E ratio is -37.05. In terms of profitability, RXRX's ROE is -0.76%, compared to ASND's ROE of +1.91%. Regarding short-term risk, RXRX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check ASND's competition here
RXRX vs BMRN Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, RXRX is priced at $5.48, while BMRN trades at $60.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas BMRN's P/E ratio is 16.76. In terms of profitability, RXRX's ROE is -0.76%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, RXRX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check BMRN's competition here
RXRX vs EXEL Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, EXEL has a market cap of 10.1B. Regarding current trading prices, RXRX is priced at $5.48, while EXEL trades at $37.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas EXEL's P/E ratio is 17.99. In terms of profitability, RXRX's ROE is -0.76%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, RXRX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check EXEL's competition here
RXRX vs MRNA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MRNA has a market cap of 9.9B. Regarding current trading prices, RXRX is priced at $5.48, while MRNA trades at $26.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MRNA's P/E ratio is -3.39. In terms of profitability, RXRX's ROE is -0.76%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, RXRX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check MRNA's competition here
RXRX vs RXDX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RXRX is priced at $5.48, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RXRX's ROE is -0.76%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RXRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check RXDX's competition here
RXRX vs BBIO Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, BBIO has a market cap of 9.2B. Regarding current trading prices, RXRX is priced at $5.48, while BBIO trades at $44.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas BBIO's P/E ratio is -11.68. In terms of profitability, RXRX's ROE is -0.76%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, RXRX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check BBIO's competition here
RXRX vs VRNA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, RXRX is priced at $5.48, while VRNA trades at $105.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas VRNA's P/E ratio is -101.19. In terms of profitability, RXRX's ROE is -0.76%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, RXRX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check VRNA's competition here
RXRX vs IMGN Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RXRX is priced at $5.48, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RXRX's ROE is -0.76%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, RXRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check IMGN's competition here
RXRX vs BPMC Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RXRX is priced at $5.48, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RXRX's ROE is -0.76%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RXRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check BPMC's competition here
RXRX vs CERE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RXRX is priced at $5.48, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CERE's P/E ratio is -16.47. In terms of profitability, RXRX's ROE is -0.76%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RXRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check CERE's competition here
RXRX vs TECH Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, TECH has a market cap of 7.9B. Regarding current trading prices, RXRX is priced at $5.48, while TECH trades at $49.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas TECH's P/E ratio is 109.02. In terms of profitability, RXRX's ROE is -0.76%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RXRX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check TECH's competition here
RXRX vs ROIVW Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, RXRX is priced at $5.48, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RXRX's ROE is -0.76%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, RXRX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check ROIVW's competition here
RXRX vs MDGL Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MDGL has a market cap of 7.8B. Regarding current trading prices, RXRX is priced at $5.48, while MDGL trades at $338.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MDGL's P/E ratio is -27.63. In terms of profitability, RXRX's ROE is -0.76%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, RXRX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check MDGL's competition here
RXRX vs ROIV Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ROIV has a market cap of 7.6B. Regarding current trading prices, RXRX is priced at $5.48, while ROIV trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ROIV's P/E ratio is -14.89. In terms of profitability, RXRX's ROE is -0.76%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, RXRX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ROIV's competition here
RXRX vs CORT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, RXRX is priced at $5.48, while CORT trades at $70.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CORT's P/E ratio is 64.26. In terms of profitability, RXRX's ROE is -0.76%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RXRX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check CORT's competition here
RXRX vs HALO Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, RXRX is priced at $5.48, while HALO trades at $62.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas HALO's P/E ratio is 14.40. In terms of profitability, RXRX's ROE is -0.76%, compared to HALO's ROE of +1.37%. Regarding short-term risk, RXRX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check HALO's competition here
RXRX vs JAZZ Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, RXRX is priced at $5.48, while JAZZ trades at $105.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas JAZZ's P/E ratio is -15.87. In terms of profitability, RXRX's ROE is -0.76%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, RXRX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check JAZZ's competition here
RXRX vs RETA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RXRX is priced at $5.48, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RETA's P/E ratio is -66.29. In terms of profitability, RXRX's ROE is -0.76%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RXRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check RETA's competition here
RXRX vs IONS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, RXRX is priced at $5.48, while IONS trades at $40.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas IONS's P/E ratio is -23.20. In terms of profitability, RXRX's ROE is -0.76%, compared to IONS's ROE of -0.45%. Regarding short-term risk, RXRX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check IONS's competition here
RXRX vs RVMD Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RVMD has a market cap of 6.5B. Regarding current trading prices, RXRX is priced at $5.48, while RVMD trades at $36.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RVMD's P/E ratio is -7.68. In terms of profitability, RXRX's ROE is -0.76%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, RXRX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check RVMD's competition here
RXRX vs RYTM Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, RXRX is priced at $5.48, while RYTM trades at $90.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RYTM's P/E ratio is -31.33. In terms of profitability, RXRX's ROE is -0.76%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, RXRX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check RYTM's competition here
RXRX vs RNA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RNA has a market cap of 5.9B. Regarding current trading prices, RXRX is priced at $5.48, while RNA trades at $48.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RNA's P/E ratio is -15.25. In terms of profitability, RXRX's ROE is -0.76%, compared to RNA's ROE of -0.33%. Regarding short-term risk, RXRX is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check RNA's competition here
RXRX vs ABCM Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RXRX is priced at $5.48, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RXRX's ROE is -0.76%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RXRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ABCM's competition here
RXRX vs ISEE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RXRX is priced at $5.48, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RXRX's ROE is -0.76%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RXRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ISEE's competition here
RXRX vs NUVL Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, RXRX is priced at $5.48, while NUVL trades at $77.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas NUVL's P/E ratio is -15.23. In terms of profitability, RXRX's ROE is -0.76%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, RXRX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check NUVL's competition here
RXRX vs ABVX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ABVX has a market cap of 5.2B. Regarding current trading prices, RXRX is priced at $5.48, while ABVX trades at $69.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ABVX's P/E ratio is -20.06. In terms of profitability, RXRX's ROE is -0.76%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, RXRX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check ABVX's competition here
RXRX vs AXSM Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, RXRX is priced at $5.48, while AXSM trades at $103.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas AXSM's P/E ratio is -20.55. In terms of profitability, RXRX's ROE is -0.76%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, RXRX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check AXSM's competition here
RXRX vs CRSP Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, RXRX is priced at $5.48, while CRSP trades at $56.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CRSP's P/E ratio is -10.26. In terms of profitability, RXRX's ROE is -0.76%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, RXRX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check CRSP's competition here
RXRX vs MRUS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, RXRX is priced at $5.48, while MRUS trades at $65.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MRUS's P/E ratio is -11.58. In terms of profitability, RXRX's ROE is -0.76%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, RXRX is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check MRUS's competition here
RXRX vs SLNO Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, SLNO has a market cap of 4.6B. Regarding current trading prices, RXRX is priced at $5.48, while SLNO trades at $81.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas SLNO's P/E ratio is -20.32. In terms of profitability, RXRX's ROE is -0.76%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, RXRX is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check SLNO's competition here
RXRX vs ALPN Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RXRX is priced at $5.48, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RXRX's ROE is -0.76%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RXRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ALPN's competition here
RXRX vs ALKS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, RXRX is priced at $5.48, while ALKS trades at $26.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ALKS's P/E ratio is 12.82. In terms of profitability, RXRX's ROE is -0.76%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, RXRX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ALKS's competition here
RXRX vs VKTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, RXRX is priced at $5.48, while VKTX trades at $31.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas VKTX's P/E ratio is -24.82. In terms of profitability, RXRX's ROE is -0.76%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, RXRX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check VKTX's competition here
RXRX vs OPT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $5.48, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas OPT's P/E ratio is -1.52. In terms of profitability, RXRX's ROE is -0.76%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RXRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check OPT's competition here
RXRX vs TGTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, TGTX has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $5.48, while TGTX trades at $27.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas TGTX's P/E ratio is 69.45. In terms of profitability, RXRX's ROE is -0.76%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, RXRX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check TGTX's competition here
RXRX vs ACAD Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, RXRX is priced at $5.48, while ACAD trades at $23.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ACAD's P/E ratio is 18.66. In terms of profitability, RXRX's ROE is -0.76%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, RXRX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ACAD's competition here
RXRX vs MRTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RXRX is priced at $5.48, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RXRX's ROE is -0.76%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RXRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check MRTX's competition here
RXRX vs KRYS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, RXRX is priced at $5.48, while KRYS trades at $136.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas KRYS's P/E ratio is 27.96. In terms of profitability, RXRX's ROE is -0.76%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, RXRX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check KRYS's competition here
RXRX vs CYTK Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, RXRX is priced at $5.48, while CYTK trades at $35.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CYTK's P/E ratio is -6.49. In terms of profitability, RXRX's ROE is -0.76%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, RXRX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check CYTK's competition here
RXRX vs ADMA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ADMA has a market cap of 3.9B. Regarding current trading prices, RXRX is priced at $5.48, while ADMA trades at $18.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ADMA's P/E ratio is 19.31. In terms of profitability, RXRX's ROE is -0.76%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, RXRX is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check ADMA's competition here
RXRX vs PCVX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, PCVX has a market cap of 3.9B. Regarding current trading prices, RXRX is priced at $5.48, while PCVX trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas PCVX's P/E ratio is -7.22. In terms of profitability, RXRX's ROE is -0.76%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RXRX and PCVX have similar daily volatility (3.90).Check PCVX's competition here
RXRX vs AKRO Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.48, while AKRO trades at $52.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas AKRO's P/E ratio is -12.87. In terms of profitability, RXRX's ROE is -0.76%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RXRX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check AKRO's competition here
RXRX vs ACLX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.48, while ACLX trades at $70.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ACLX's P/E ratio is -20.26. In terms of profitability, RXRX's ROE is -0.76%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, RXRX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ACLX's competition here
RXRX vs ZLAB Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.48, while ZLAB trades at $38.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ZLAB's P/E ratio is -17.33. In terms of profitability, RXRX's ROE is -0.76%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, RXRX is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check ZLAB's competition here
RXRX vs AAPG Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, AAPG has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.48, while AAPG trades at $42.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas AAPG's P/E ratio is -54.84. In terms of profitability, RXRX's ROE is -0.76%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RXRX is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check AAPG's competition here
RXRX vs RYZB Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RXRX is priced at $5.48, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RXRX's ROE is -0.76%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RXRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check RYZB's competition here
RXRX vs CBAY Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RXRX is priced at $5.48, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RXRX's ROE is -0.76%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RXRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check CBAY's competition here
RXRX vs TLX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, RXRX is priced at $5.48, while TLX trades at $11.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas TLX's P/E ratio is 121.00. In terms of profitability, RXRX's ROE is -0.76%, compared to TLX's ROE of +0.10%. Regarding short-term risk, RXRX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check TLX's competition here
RXRX vs SWTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RXRX is priced at $5.48, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RXRX's ROE is -0.76%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RXRX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check SWTX's competition here
RXRX vs PTCT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, PTCT has a market cap of 3.4B. Regarding current trading prices, RXRX is priced at $5.48, while PTCT trades at $51.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas PTCT's P/E ratio is 6.14. In terms of profitability, RXRX's ROE is -0.76%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, RXRX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check PTCT's competition here
RXRX vs MLTX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, RXRX is priced at $5.48, while MLTX trades at $52.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MLTX's P/E ratio is -19.13. In terms of profitability, RXRX's ROE is -0.76%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, RXRX is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check MLTX's competition here
RXRX vs PTGX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, RXRX is priced at $5.48, while PTGX trades at $53.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas PTGX's P/E ratio is 73.63. In terms of profitability, RXRX's ROE is -0.76%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, RXRX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check PTGX's competition here
RXRX vs LEGN Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, RXRX is priced at $5.48, while LEGN trades at $37.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas LEGN's P/E ratio is -30.71. In terms of profitability, RXRX's ROE is -0.76%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, RXRX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check LEGN's competition here
RXRX vs MIRM Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MIRM has a market cap of 3.3B. Regarding current trading prices, RXRX is priced at $5.48, while MIRM trades at $53.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MIRM's P/E ratio is -54.44. In terms of profitability, RXRX's ROE is -0.76%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, RXRX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check MIRM's competition here
RXRX vs MTSR Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, RXRX is priced at $5.48, while MTSR trades at $33.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MTSR's P/E ratio is -10.29. In terms of profitability, RXRX's ROE is -0.76%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, RXRX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check MTSR's competition here
RXRX vs SRRK Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, SRRK has a market cap of 3B. Regarding current trading prices, RXRX is priced at $5.48, while SRRK trades at $34.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas SRRK's P/E ratio is -10.77. In terms of profitability, RXRX's ROE is -0.76%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, RXRX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check SRRK's competition here
RXRX vs APLS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, APLS has a market cap of 3B. Regarding current trading prices, RXRX is priced at $5.48, while APLS trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas APLS's P/E ratio is -13.03. In terms of profitability, RXRX's ROE is -0.76%, compared to APLS's ROE of -1.16%. Regarding short-term risk, RXRX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check APLS's competition here
RXRX vs MORF Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RXRX is priced at $5.48, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MORF's P/E ratio is -14.88. In terms of profitability, RXRX's ROE is -0.76%, compared to MORF's ROE of -0.16%. Regarding short-term risk, RXRX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check MORF's competition here
RXRX vs MOR Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RXRX is priced at $5.48, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MOR's P/E ratio is -12.64. In terms of profitability, RXRX's ROE is -0.76%, compared to MOR's ROE of -1.84%. Regarding short-term risk, RXRX is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check MOR's competition here
RXRX vs LGND Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, LGND has a market cap of 2.8B. Regarding current trading prices, RXRX is priced at $5.48, while LGND trades at $142.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas LGND's P/E ratio is -36.03. In terms of profitability, RXRX's ROE is -0.76%, compared to LGND's ROE of -0.09%. Regarding short-term risk, RXRX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check LGND's competition here
RXRX vs NAMS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, NAMS has a market cap of 2.7B. Regarding current trading prices, RXRX is priced at $5.48, while NAMS trades at $23.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas NAMS's P/E ratio is -15.33. In terms of profitability, RXRX's ROE is -0.76%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, RXRX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check NAMS's competition here
RXRX vs KDNY Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, RXRX is priced at $5.48, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RXRX's ROE is -0.76%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RXRX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check KDNY's competition here
RXRX vs KYMR Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, KYMR has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.48, while KYMR trades at $41.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas KYMR's P/E ratio is -12.12. In terms of profitability, RXRX's ROE is -0.76%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, RXRX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check KYMR's competition here
RXRX vs RARE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.48, while RARE trades at $28.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas RARE's P/E ratio is -5.00. In terms of profitability, RXRX's ROE is -0.76%, compared to RARE's ROE of -2.37%. Regarding short-term risk, RXRX is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check RARE's competition here
RXRX vs MYOV Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.48, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RXRX's ROE is -0.76%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RXRX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check MYOV's competition here
RXRX vs XENE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.48, while XENE trades at $34.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas XENE's P/E ratio is -10.59. In terms of profitability, RXRX's ROE is -0.76%, compared to XENE's ROE of -0.32%. Regarding short-term risk, RXRX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check XENE's competition here
RXRX vs CRNX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CRNX has a market cap of 2.6B. Regarding current trading prices, RXRX is priced at $5.48, while CRNX trades at $28.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CRNX's P/E ratio is -6.68. In terms of profitability, RXRX's ROE is -0.76%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, RXRX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check CRNX's competition here
RXRX vs IMVT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, IMVT has a market cap of 2.5B. Regarding current trading prices, RXRX is priced at $5.48, while IMVT trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas IMVT's P/E ratio is -5.41. In terms of profitability, RXRX's ROE is -0.76%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, RXRX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check IMVT's competition here
RXRX vs KNSA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, RXRX is priced at $5.48, while KNSA trades at $32.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas KNSA's P/E ratio is 654.80. In terms of profitability, RXRX's ROE is -0.76%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, RXRX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check KNSA's competition here
RXRX vs CPRX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CPRX has a market cap of 2.4B. Regarding current trading prices, RXRX is priced at $5.48, while CPRX trades at $21.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CPRX's P/E ratio is 11.93. In terms of profitability, RXRX's ROE is -0.76%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, RXRX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check CPRX's competition here
RXRX vs ARWR Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, ARWR has a market cap of 2.4B. Regarding current trading prices, RXRX is priced at $5.48, while ARWR trades at $16.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas ARWR's P/E ratio is -13.88. In terms of profitability, RXRX's ROE is -0.76%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, RXRX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check ARWR's competition here
RXRX vs PRVB Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, RXRX is priced at $5.48, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RXRX's ROE is -0.76%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RXRX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check PRVB's competition here
RXRX vs LBPH Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, RXRX is priced at $5.48, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RXRX's ROE is -0.76%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, RXRX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check LBPH's competition here
RXRX vs IBRX Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, RXRX is priced at $5.48, while IBRX trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas IBRX's P/E ratio is -5.15. In terms of profitability, RXRX's ROE is -0.76%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, RXRX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check IBRX's competition here
RXRX vs DICE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, RXRX is priced at $5.48, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas DICE's P/E ratio is -21.91. In terms of profitability, RXRX's ROE is -0.76%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RXRX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check DICE's competition here
RXRX vs BLTE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, RXRX is priced at $5.48, while BLTE trades at $67.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas BLTE's P/E ratio is -51.10. In terms of profitability, RXRX's ROE is -0.76%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, RXRX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check BLTE's competition here
RXRX vs CNTA Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CNTA has a market cap of 2.2B. Regarding current trading prices, RXRX is priced at $5.48, while CNTA trades at $17.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CNTA's P/E ratio is -8.84. In terms of profitability, RXRX's ROE is -0.76%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, RXRX is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check CNTA's competition here
RXRX vs VCYT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, RXRX is priced at $5.48, while VCYT trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas VCYT's P/E ratio is 82.32. In terms of profitability, RXRX's ROE is -0.76%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, RXRX is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check VCYT's competition here
RXRX vs OCUL Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, RXRX is priced at $5.48, while OCUL trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas OCUL's P/E ratio is -9.97. In terms of profitability, RXRX's ROE is -0.76%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, RXRX is less volatile compared to OCUL. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check OCUL's competition here
RXRX vs CALT Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.48, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas CALT's P/E ratio is -22.73. In terms of profitability, RXRX's ROE is -0.76%, compared to CALT's ROE of -1.67%. Regarding short-term risk, RXRX is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check CALT's competition here
RXRX vs TARS Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, TARS has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.48, while TARS trades at $41.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas TARS's P/E ratio is -21.86. In terms of profitability, RXRX's ROE is -0.76%, compared to TARS's ROE of -0.32%. Regarding short-term risk, RXRX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check TARS's competition here
RXRX vs GLPG Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, GLPG has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.48, while GLPG trades at $32.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas GLPG's P/E ratio is -6.16. In terms of profitability, RXRX's ROE is -0.76%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, RXRX is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check GLPG's competition here
RXRX vs APGE Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, APGE has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.48, while APGE trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas APGE's P/E ratio is -9.60. In terms of profitability, RXRX's ROE is -0.76%, compared to APGE's ROE of -0.19%. Regarding short-term risk, RXRX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check APGE's competition here
RXRX vs FOLD Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, FOLD has a market cap of 2.1B. Regarding current trading prices, RXRX is priced at $5.48, while FOLD trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas FOLD's P/E ratio is -55.46. In terms of profitability, RXRX's ROE is -0.76%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, RXRX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RXRX.Check FOLD's competition here
RXRX vs AGIO Comparison August 2025
RXRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXRX stands at 2.3B. In comparison, AGIO has a market cap of 2B. Regarding current trading prices, RXRX is priced at $5.48, while AGIO trades at $37.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXRX currently has a P/E ratio of -2.92, whereas AGIO's P/E ratio is 3.11. In terms of profitability, RXRX's ROE is -0.76%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, RXRX is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for RXRX.Check AGIO's competition here